David Browning



David joined OBN as a non-executive director in December 2018, becoming Chairman in September 2020. David applies more than 40 years experience of innovation translation experience across Life Sciences, most recently as CEO of Fixed Phage (where he continues as a business advisor), with a focus on addressing the rapidly increasing prevalence of antibiotic resistance. 

He has advised numerous successful businesses across health, life-sciences and nanotechnology with an ambition to improve standards of care and health economic outcomes. Previous roles include CEO of Oxford Cancer Biomarkers, Senior Vice President, Development and Innovation of the BioCity Group and Managing Director of MediCity, supporting new life science business creation and accelerating growth. 

David was CEO of disruptive innovation ventures within Philips, incorporating companion diagnostics into the Philips Digital Pathology business. He has successfully driven innovation within Amersham International, Johnson & Johnson, IGEN International and Oxonica Healthcare, an Oxford University spin-out. David commenced his career as a Biomedical Scientist within the NHS, gaining his MSc in Biochemical Immunology. David is actively involved in sport, representing Great Britain as an age-group athlete in Cross Triathlon and is engaged with coaching and inspiring young people to improve their wellbeing through positive lifestyle choices.